Online citations, reference lists, and bibliographies.

Blood Pressure Targets In Type 2 Diabetes. Evidence Against Or In Favour Of An Aggressive Approach

G. Mancia, G. Grassi
Published 2017 · Biology, Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
When associated with high blood pressure, type 2 diabetes mellitus is characterised by a high risk of adverse cardiovascular (CV) and renal outcomes. However, both can be effectively reduced by antihypertensive treatment. Current guidelines on the treatment of hypertension emphasize the need to effectively treat high blood pressure in diabetic individuals, but their recommendations differ in terms of the optimal target blood pressure value to aim for in order to maximise CV and renal protection. In some guidelines the recommended target blood pressure values are <140/90 mmHg (systolic/diastolic), whereas in others, blood pressure values close or even less than 130/80 mmHg are recommended. This paper will discuss the evidence for and against a conservative or more aggressive blood pressure target for treated diabetic hypertensive individuals based on the evidence provided by randomised trials, trial meta-analyses and large observational studies. Based on the available evidence, it appears that blood pressure targets will probably have to be lower than <140/90 mmHg, and that values approaching 130/80 mmHg should be recommended. However, evidence in favour of even lower systolic values, i.e. <130 mmHg, is limited and is definitively against a reduction to <120 mmHg.
This paper references
10.1038/ki.2011.415
Combined intensive blood pressure and glycemic control does not produce an additive benefit on microvascular outcomes in type 2 diabetic patients.
F. Ismail-Beigi (2012)
10.1093/eurheartj/ehz486
2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD.
F. Cosentino (2019)
Preferential stiffening of central over peripheral arteries in type 2 diabetes
木本 栄司 (2003)
10.1161/CIRCULATIONAHA.110.016337
Blood Pressure Targets in Subjects With Type 2 Diabetes Mellitus/Impaired Fasting Glucose: Observations From Traditional and Bayesian Random-Effects Meta-Analyses of Randomized Trials
S. Bangalore (2011)
10.1681/ASN.2010091001
Changes in albuminuria predict mortality and morbidity in patients with vascular disease.
R. Schmieder (2011)
10.1016/S0140-6736(98)04311-6
Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial
L. Hansson (1998)
10.1097/HJH.0B013E3281FC975A
2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC)
G. Mancia (2007)
10.1161/HYPERTENSIONAHA.114.04273
Prognostic Value of Microalbuminuria During Antihypertensive Treatment in Essential Hypertension
J. M. Pascual (2014)
10.1001/jama.2014.18574
Blood pressure lowering in type 2 diabetes: a systematic review and meta-analysis.
C. Emdin (2015)
10.1093/eurheartj/ehz687
The 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD.
P. Grant (2019)
10.1097/HJH.0000000000001515
Achieving target SBP for lowering the risk of major adverse cardiovascular events in persons with diabetes mellitus
B. ó Hartaigh (2018)
10.1525/9780520953703-011
“10”
A. M. Levine (2003)
10.1093/eurheartj/ehv633
Cardiovascular outcomes at different on-treatment blood pressures in the hypertensive patients of the VALUE trial.
G. Mancia (2016)
10.2337/dc12-s011
Standards of Medical Care in Diabetes—2012
Vittorio Basevi (2011)
Patterns of hypertension management in Italy: results of a pharmacoepidemiological survey on antihypertensive therapy
O. Maggiore (2000)
10.1001/jama.2013.284427
2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8).
P. James (2014)
10.3109/08037050903450468
Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document
G. Mancia (2009)
10.1016/j.jacc.2011.09.040
Safety and efficacy of low blood pressures among patients with diabetes: subgroup analyses from the ONTARGET (ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial).
J. Redon (2012)
10.1016/j.amjmed.2013.01.007
Systolic blood pressure and cardiovascular outcomes during treatment of hypertension.
M. Weber (2013)
10.1161/CIRCRESAHA.116.303641
Randomized controlled trials of blood pressure lowering in hypertension: a critical reappraisal.
A. Zanchetti (2015)
10.1161/STROKEAHA.112.651448
Effects of Blood Pressure Lowering on Intracranial and Extracranial Bleeding in Patients on Antithrombotic Therapy: The PROGRESS Trial
H. Arima (2012)
10.1097/HJH.0000000000000972
Effects of blood pressure lowering treatment in hypertension: 8. Outcome reductions vs. discontinuations because of adverse drug events – meta-analyses of randomized trials
C. Thomopoulos (2016)
10.1681/ASN.2005091012
Association of single measurements of dipstick proteinuria, estimated glomerular filtration rate, and hematocrit with 25-year incidence of end-stage renal disease in the multiple risk factor intervention trial.
A. Ishani (2006)
10.1161/HYPERTENSIONAHA.114.03883
Ambulatory Blood Pressure Monitoring Is Ready to Replace Clinic Blood Pressure in the Diagnosis of Hypertension: Con Side of the Argument
Josep Redon (2014)
10.1016/S0140-6736(09)61378-7
Albuminuria in chronic heart failure: prevalence and prognostic importance
C. Jackson (2009)
10.7326/0003-4819-151-6-200909150-00137
Systematic Review: Glucose Control and Cardiovascular Disease in Type 2 Diabetes
T. Kelly (2009)
10.1056/NEJMoa1007994
Olmesartan for the delay or prevention of microalbuminuria in type 2 diabetes.
H. Haller (2011)
10.1046/J.1523-1755.2002.00213.X
Effects of aggressive blood pressure control in normotensive type 2 diabetic patients on albuminuria, retinopathy and strokes.
R. Schrier (2002)
10.1016/S0145-4145(08)79430-9
Benazepril plus Amlodipine or Hydrochlorothiazide for Hypertension in High-Risk Patients
W. Elliott (2009)
Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack
S. Pinto (2001)
10.1056/NEJMoa1001286
Effects of intensive blood-pressure control in type 2 diabetes mellitus.
W. Cushman (2010)
10.1097/HJH.0b013e32832aa6b5
When should antihypertensive drug treatment be initiated and to what levels should systolic blood pressure be lowered? A critical reappraisal
A. Zanchetti (2009)
10.1007/s001250051257
Early impairment of large artery structure and function in Type I diabetes mellitus
C. Giannattasio (1999)
10.1007/s00125-014-3330-9
Mortality and morbidity in relation to changes in albuminuria, glucose status and systolic blood pressure: an analysis of the ONTARGET and TRANSCEND studies
R. E. Schmieder (2014)
Randomised trial of a perindopril-based blood pressure lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack
S. MacMahon (2001)
10.1097/HJH.0000000000001276
Effects of blood-pressure-lowering treatment on outcome incidence in hypertension: 10 – Should blood pressure management differ in hypertensive patients with and without diabetes mellitus? Overview and meta-analyses of randomized trials
C. Thomopoulos (2017)
Effects of intensive bloodpressure control in type 2 diabetes mellitus
AK Boehme (2010)
10.1016/S0140-6736(07)61303-8
Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial
A. Patel (2007)
10.1007/s00059-006-2829-3
ESH-ESC Guidelines for the Management of Hypertension
S. Erdine (2006)
Effects of blood pressure lowering treatment in hypertension : 8 . Outcome reductions vs discontinuations because of adverse eventsmetaanalisys of randomized trials
C Thomopoulos (2016)
10.2337/dc11-0262
Response to Comment on: American Diabetes Association. Standards of Medical Care in Diabetes—2011. Diabetes Care 2011;34(Suppl. 1):S11–S61
C. Wysham (2011)
10.1007/s001250050851
Time and frequency domain estimates of spontaneous baroreflex sensitivity provide early detection of autonomic dysfunction in diabetes mellitus
A. Frattola (1997)
10.1097/00004872-200208000-00001
Systolic and diastolic blood pressure control in antihypertensive drug trials.
G. Mancia (2002)
10.1136/jnnp-2014-307856
Degree of blood pressure reduction and recurrent stroke: the PROGRESS trial
H. Arima (2014)
10.1097/HJH.0b013e3283469976
Effects of intensive blood pressure reduction on myocardial infarction and stroke in diabetes: a meta-analysis in 73 913 patients
G. Reboldi (2011)
10.1056/NEJMoa1208799
Cardiorenal end points in a trial of aliskiren for type 2 diabetes.
Hans‐Henrik Parving (2012)
10.1161/01.hyp.0000441190.09494.e9
Aggressive blood pressure lowering is dangerous: the J-curve: pro side of the arguement.
G. Mancia (2014)
10.1161/HYPERTENSIONAHA.115.06480
Achieved Blood Pressure and Outcomes in the Secondary Prevention of Small Subcortical Strokes Trial
M. Odden (2016)
Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group.
R. Turner (1998)
10.1161/HYPERTENSIONAHA.113.01922
Aggressive Blood Pressure Lowering Is Dangerous: The J-Curve Pro Side of the Argument
G. Mancia (2014)
10.2337/DIACARE.29.02.06.DC05-1989
Standards of Medical Care in Diabetes: Response to Power
V. Fonseca (2006)
10.1097/HJH.0000000000000841
Risks associated with permanent discontinuation of blood pressure-lowering medications in patients with type 2 diabetes
Y. Hirakawa (2016)
Risk associated with permanent discontinuation of blood pressure lowering medications in patients with type 2 diabetes
Y Hirakawa (2016)
10.1001/jama.2010.884
Tight blood pressure control and cardiovascular outcomes among hypertensive patients with diabetes and coronary artery disease.
R. Cooper-DeHoff (2010)
10.1016/j.jacc.2017.11.006
2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.
P. Whelton (2018)
10.1136/bmj.i717
Effect of antihypertensive treatment at different blood pressure levels in patients with diabetes mellitus: systematic review and meta-analyses
M. Brunström (2016)
10.2337/dc13-2334
Outcomes of Combined Cardiovascular Risk Factor Management Strategies in Type 2 Diabetes: The ACCORD Randomized Trial
K. Margolis (2014)
Randomised trial of a perindoprilbased blood pressure lowering regimen among individuals with previous stroke or transient ischaemic attack
H Arima (2001)
10.7326/0003-4819-123-10-199511150-00003
Blood Pressure Control, Proteinuria, and the Progression of Renal Disease
J. Peterson (1995)
A (2015) Blood pressure lowering in type 2 diabetes. A systematic review and meta-analysis
CA Emdin (2015)
A et al (2016) Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis
D Ettehad (2016)
10.1016/S0140-6736(15)01225-8
Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis
Dena Ettehad (2016)
10.1161/CIRCRESAHA.116.308398
Stroke Risk Factors, Genetics, and Prevention
A. Boehme (2017)
10.1038/nrneurol.2010.114
Secondary stroke prevention
J. Spence (2010)



This paper is referenced by
10.1093/eurheartj/ehz486
2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD.
F. Cosentino (2019)
10.1161/CIRCRESAHA.118.313294
Two-Drug Combinations as First-Step Antihypertensive Treatment.
Giuseppe Mancia (2019)
10.2337/dc17-2443
Effect of Achieved Systolic Blood Pressure on Cardiovascular Outcomes in Patients With Type 2 Diabetes: A Population-Based Retrospective Cohort Study
E. Wan (2018)
10.36290/lek.2018.033
Effect of diabetic nephropathy on drug pharmacokinetics
Eliška Dvořáčková (2018)
10.1016/j.recesp.2019.11.024
Guía ESC 2019 sobre diabetes, prediabetes y enfermedades cardiovasculares, en colaboración con la European Association for the Study of Diabetes (EASD)
F. Cosentino (2020)
10.1007/s00508-019-01565-0
[Austrian Consensus on High Blood Pressure 2019].
T. Weber (2019)
10.1007/s11255-018-02064-3
The impact of antihypertensive pharmacotherapy on interplay between protein-bound uremic toxin (indoxyl sulfate) and markers of inflammation in patients with chronic kidney disease
Tomasz W. Kaminski (2018)
10.1080/08037051.2020.1750298
Influence of pre-treatment blood pressure levels on antihypertensive drug benefits in diabetics: the roadmap experience
C. Chatzikyrkou (2020)
10.1007/s00508-019-1460-2
Individualisierung der antihypertensiven Therapie bei Patienten mit Diabetes mellitus. Leitlinie der Österreichischen Diabetes Gesellschaft (Update 2019)
G. Schernthaner (2019)
10.2337/dc19-0686
Association Between Early Hypertension Control and Cardiovascular Disease Incidence in Veterans With Diabetes
S. Raghavan (2019)
Semantic Scholar Logo Some data provided by SemanticScholar